Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma

MLA

L E, Flaherty. “Rationale for Intergroup Trial E-3695 Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, and DTIC Alone in Patients with Metastatic Melanoma.” The Cancer Journal from Scientific American, vol. 6, Feb. 2000. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........8809133370b5ac3d77e3a4e053d5cf6f&authtype=sso&custid=ns315887.

APA

L E, F. (2000). Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. The Cancer Journal from Scientific American, 6.

Chicago

L E, Flaherty. 2000. “Rationale for Intergroup Trial E-3695 Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, and DTIC Alone in Patients with Metastatic Melanoma.” The Cancer Journal from Scientific American 6 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........8809133370b5ac3d77e3a4e053d5cf6f&authtype=sso&custid=ns315887.